200 related articles for article (PubMed ID: 37171706)
1. The rationale for intermittent administration of PTH in the management of mineral and bone disorder of chronic kidney disease.
Pazianas M; Miller PD
J Nephrol; 2024 Mar; 37(2):337-342. PubMed ID: 37171706
[TBL] [Abstract][Full Text] [Related]
2. The CKD-MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management.
Pazianas M; Miller PD
J Bone Miner Res; 2020 Dec; 35(12):2313-2317. PubMed ID: 32780482
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Koizumi M; Komaba H; Fukagawa M
Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics.
Pazianas M; Miller PD
Am J Kidney Dis; 2021 Oct; 78(4):582-589. PubMed ID: 33774081
[TBL] [Abstract][Full Text] [Related]
6. Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease.
Parker VJ; Harjes LM; Dembek K; Young GS; Chew DJ; Toribio RE
J Vet Intern Med; 2017 May; 31(3):791-798. PubMed ID: 28186657
[TBL] [Abstract][Full Text] [Related]
7. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
8. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.
Kalantar-Zadeh K; Shah A; Duong U; Hechter RC; Dukkipati R; Kovesdy CP
Kidney Int Suppl; 2010 Aug; (117):S10-21. PubMed ID: 20671739
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
Evenepoel P; Meijers B; Viaene L; Bammens B; Claes K; Kuypers D; Vanderschueren D; Vanrenterghem Y
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1268-76. PubMed ID: 20448073
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
12. [Vitamin D metabolism and chronic kidney disease].
Honda H; Sanada D; Akizawa T
Clin Calcium; 2006 Jul; 16(7):1143-46. PubMed ID: 16816474
[TBL] [Abstract][Full Text] [Related]
13. CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?
Melamed ML; Buttar RS; Coco M
Adv Chronic Kidney Dis; 2016 Jul; 23(4):262-9. PubMed ID: 27324680
[TBL] [Abstract][Full Text] [Related]
14. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.
Diniz H; Frazão JM
Nefrologia; 2013 Nov; 33(6):835-44. PubMed ID: 24158124
[TBL] [Abstract][Full Text] [Related]
15. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
16. Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management.
Pazianas M; Miller PD
J Bone Metab; 2020 Feb; 27(1):1-13. PubMed ID: 32190604
[TBL] [Abstract][Full Text] [Related]
17. Chronic kidney disease: mineral and bone disorder in children.
Wesseling-Perry K; Salusky IB
Semin Nephrol; 2013 Mar; 33(2):169-79. PubMed ID: 23465503
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.
Malhotra R; Katz R; Hoofnagle A; Bostom A; Rifkin DE; Mcbride R; Probstfield J; Block G; Ix JH
Clin J Am Soc Nephrol; 2018 Jan; 13(1):36-44. PubMed ID: 29208626
[TBL] [Abstract][Full Text] [Related]
20. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
Thadhani RI; Rosen S; Ofsthun NJ; Usvyat LA; Dalrymple LS; Maddux FW; Hymes JL
Clin J Am Soc Nephrol; 2020 Mar; 15(3):384-391. PubMed ID: 32111702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
